Imago BioSciences, Inc., a clinical-stage biopharmaceutical company developing innovative treatments for myeloproliferative neoplasms, today announced that Hugh Young Rienhoff, Jr., M.D., CEO, will present at the 39th Annual J.P. Morgan Healthcare Conference at 4:55 p.m.
About Imago BioSciences
Imago BioSciences is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for the treatment of hematologic disorders. Imago has developed a series of compounds that inhibit LSD1, an epigenetic enzyme critical for cancer stem cell function and blood cell differentiation. The company is advancing the clinical development of its first LSD1 inhibitor, bomedemstat, for the treatment of myeloid neoplasms. Imago is backed by leading private, public and strategic investors including a fund managed by Blackstone Life Sciences, Frazier Healthcare Partners, Omega Funds, Farallon Capital Management, L.L.C., funds and accounts advised by T. Rowe Price Associates, Inc., and funds and accounts managed by Blackrock Advisors, LLC. The company is based in South San Francisco, California. To learn more, visit www.imagobio.com, www.myelofibrosisclinicalstudy.com, www.etclinicalstudy.com and follow us on Twitter @ImagoBioRx, Facebook and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005405/en/
Contacts
Media Contact:
Steve Kunszabo
Canale Communications
steve.kunszabo@canalecomm.com
(619) 849-5388
Investor Contact:
Matthew Plunkett, PhD,
Chief Financial Officer, Imago Biosciences
matthew.plunkett@imagobio.com
Source: Imago BioSciences, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20210112005405/en
